Gut bacteria test for standard lung cancer treatment
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been newly diagnosed with a type of lung cancer called non-small cell lung cancer (stage IIA to IIIB).
- You have not had chemotherapy, radiation, or other cancer treatments before.
- You are healthy enough to have surgery to remove the cancer, and your doctor agrees that you can have the study treatment first.
- You have not taken antibiotics or probiotics (like yogurt with live cultures or supplements) in the past 3 months.
- You do not have other serious health conditions (like uncontrolled diabetes, heart failure, or autoimmune diseases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
This study looks at gut bacteria in people with colorectal cancer that has spread (metastatic). It aims to find patterns in the bacteria that may help doctors choose better treatments.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This study looks at whether certain drugs (like antibiotics or other gut-bacteria-affecting medications) influence how well immunotherapy works for advanced non-small cell lung cancer. It may help find ways to improve treatment outcomes.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.